disease

(redirected from Fabry's disease)
Also found in: Dictionary, Medical, Legal, Encyclopedia, Wikipedia.
Related to Fabry's disease: Pompe disease
  • noun

Synonyms for disease

Synonyms for disease

a pathological condition of mind or body

Words related to disease

References in periodicals archive ?
Fukuhara N, Suzuki M, Fujita N, Tsubaki T Fabry's disease on the mechanism of the peripheral nerve involvement.
Fabry's disease is an X-linked disorder of glycosphingolipid catabolism that results from the defective activity of glycosphingolipid, mainly ceramide trihexoside, in the vascular smooth muscle, myocardium, cells of sympathetic central nervous system, and epithelial cells of renal glomeruli.
Fabry's disease is an X-linked recessive disorder of glycosphingolipid catabolism caused by a deficiency of the lysosomal enzyme [alpha]-galactosidase A as a consequence of one or more than four dozen mutations.
The echocardiographic data are interesting and unique, because this report describes the first published case of Fabry's disease and restrictive physiology without any signs of hypertrophic cardiomyopathy (concentric, septal, or any other left ventricular enlargement).
Electrophysiologic findings in Fabry's disease with a short PR interval.
and the National Institutes of Health have had similar success at treating Fabry's disease with alpha-galactosidase A.
GlobalData estimates that the global Fabry's disease therapeutics market grew at a compound annual growth rate (CAGR) of 9.
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Fabry's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
Analysis of the current and future competition in the seven key countries Fabry's Disease Therapeutics market.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Fabry's Disease Therapeutics market.
Analysis of key recent licensing and partnership agreements in Fabry's Disease Therapeutics market
In addition, Neuraltus is developing NP003, an orally bioavailable, small molecule designed to treat lysosomal storage disorders such as Fabry's disease and Gaucher's disease, as well as Parkinson's disease.
Differential assay for lysosomal [alpha]-galactosidases in human tissues and its application to Fabry's disease.
This release contains a forward-looking statement about the potential effectiveness of one of our products under development in treating Fabry's disease.
HCM can easily mimic other genetic disorders, in particular Fabry's Disease and Pompe Disease.